WO2010088000A3 - Antifibrotic compounds and uses thereof - Google Patents

Antifibrotic compounds and uses thereof Download PDF

Info

Publication number
WO2010088000A3
WO2010088000A3 PCT/US2010/000287 US2010000287W WO2010088000A3 WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3 US 2010000287 W US2010000287 W US 2010000287W WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
antifibrotic compounds
antifibrotic
subclasses
classes
Prior art date
Application number
PCT/US2010/000287
Other languages
French (fr)
Other versions
WO2010088000A2 (en
Inventor
Itzhak D. Goldberg
Original Assignee
Angion Biomedica Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp. filed Critical Angion Biomedica Corp.
Publication of WO2010088000A2 publication Critical patent/WO2010088000A2/en
Publication of WO2010088000A3 publication Critical patent/WO2010088000A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present invention provides compounds having formula (I), (II) and (III): F and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and where anti-fibrotic activity is beneficial.
PCT/US2010/000287 2009-02-02 2010-02-02 Antifibrotic compounds and uses thereof WO2010088000A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20661509P 2009-02-02 2009-02-02
US61/206,615 2009-02-02
US21474409P 2009-04-28 2009-04-28
US61/214,744 2009-04-28

Publications (2)

Publication Number Publication Date
WO2010088000A2 WO2010088000A2 (en) 2010-08-05
WO2010088000A3 true WO2010088000A3 (en) 2011-04-07

Family

ID=42396268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000287 WO2010088000A2 (en) 2009-02-02 2010-02-02 Antifibrotic compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2010088000A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
BR112014015197A2 (en) 2011-12-21 2017-06-13 Novira Therapeutics Inc hepatitis b antiviral agents
ES2748873T3 (en) 2012-01-26 2020-03-18 Angion Biomedica Corp Antifibrotic compounds and uses thereof
CR20210079A (en) 2012-08-28 2021-06-10 Janssen Sciences Ireland Uc SULFAMOILARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
EA027194B1 (en) 2013-02-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
JP6419155B2 (en) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー N-phenyl-carboxamide derivatives and their use as pharmaceuticals for treating hepatitis B
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AP2015008968A0 (en) 2013-07-25 2015-12-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
ES2655518T3 (en) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Carboxamide derivatives and their use as medicines for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
MX2016009449A (en) 2014-02-05 2016-10-13 Novira Therapeutics Inc Combination therapy for treatment of hbv infections.
JP6495929B2 (en) 2014-02-06 2019-04-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Sulfamoyl pyrrolamide derivatives and their use as medicaments for the treatment of hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (en) 2015-09-29 2017-12-20 Novira Therapeutics Inc CRYSTAL FORMS OF AN ANTIVIRAL AGENT AGAINST HEPATITIS B
MX2018012557A (en) 2016-04-15 2019-07-04 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor.
JP2021515769A (en) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Capsid aggregation regulator dosing regimen
EP3927698A1 (en) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CA3132554A1 (en) 2019-05-06 2020-11-12 Bart Rudolf Romanie Kesteleyn Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063330A2 (en) * 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. (2-carboxamido) (3-amino) thiophene compounds
US20050154014A1 (en) * 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20060074082A1 (en) * 2004-09-17 2006-04-06 Arlindo Castelhano (Arylamidoaryl)cyanoguanidine compounds
WO2006070878A1 (en) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Carboxylic acid derivative or salt thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063330A2 (en) * 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. (2-carboxamido) (3-amino) thiophene compounds
US20050154014A1 (en) * 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20060074082A1 (en) * 2004-09-17 2006-04-06 Arlindo Castelhano (Arylamidoaryl)cyanoguanidine compounds
WO2006070878A1 (en) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Carboxylic acid derivative or salt thereof

Also Published As

Publication number Publication date
WO2010088000A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2011153192A3 (en) Cytochrome p450 inhibitors and uses thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2010084115A3 (en) Antiviral agents
MX2011012122A (en) Thiophene derivatives.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
MX2009013501A (en) Piperidine compounds and uses thereof.
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2011097946A8 (en) Oxazolidinone compounds containing ring-fused bicyclic ring, preparation method and use thereof
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX362830B (en) Therapeutic or prophylactic agent for biliary diseases.
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
MX2012013879A (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736165

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10736165

Country of ref document: EP

Kind code of ref document: A2